our capabilities

Uniquely integrated formulation, device and development capabilities

We effectively integrate all technologies and disciplines required to deliver an inhaled product.

next slide
next slide
next slide
next slide
Annual Report and Accounts 2017

"Delivering consistent financial results"

Read more
FAVORITE™ inhalation

Our proprietary technology, developed to improve effectiveness of inhaled drugs and deliver better clinical outcomes and shorter treatment times

Read more
Asthma fact sheet

Asthma is one of the most common non-communicable diseases

Read our Asthma fact sheet
COPD fact sheet

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease

Read our COPD fact sheet
our strategic priorities

1

Maximising
pipeline value

Maximising pipeline value

  • Leveraging rare product and device capabilities in lower risk, high-return programmes
  • Focus on:
  • Inhaled Generics
  • Vectura enhanced therapies

2

Operational
excellence

Operational excellence

  • Simplifying processes and procedures to drive operational efficiency and reduce costs
  • Managing R&D investment in line with guidance

3

Maximising
partnering value

Maximising partnering value

  • Seeking to partner existing programmes that no longer meet our investment criteria
  • Partnering new generic and enhanced delivery development programmes

4

Strong financial
discipline

Strong financial discipline

  • Leveraging strong and growing cash flows from inhaled market portfolio
  • Continued commitment to capital allocation discipline

5

High performance
culture

High performance culture

  • Ensuring our culture and behaviour are supportive of our strategic objectives
case studies
case studies

Our uniquely integrated formulation, device and development capabilities allow us to deliver the most complex products.

Breelib™ highlights our integrated development capabilities which enable us to support the development of complex inhaled products throughout the development lifecycle, from initial partner interaction, right down to product launch support and digital solution development.
Given the inherent complexity associated with developing inhaled generics, we believe that there are only a handful of companies which have the necessary capabilities to successfully develop these programmes.